Lonza Group Ltd
LO3A
Company Profile
Business description
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
Contact
Muenchensteinerstrasse 38
Basel4002
CHET: +41 613168111
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
19,299
Stocks News & Analysis
stocks
Oracle shares are up 87% in 2025. Is it a buy?
Oracle’s cloud database business is riding the AI wave.
stocks
Is there a long-term buying opportunity in luxury stocks?
Our analysts think the recent wobble in revenue growth is cyclical, not structural.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,147.00 | 24.10 | 0.26% |
| CAC 40 | 7,830.11 | 23.48 | -0.30% |
| DAX 40 | 23,527.05 | 112.36 | -0.48% |
| Dow JONES (US) | 46,381.54 | 66.27 | 0.14% |
| FTSE 100 | 9,226.68 | 10.01 | 0.11% |
| HKSE | 26,108.34 | 235.80 | -0.90% |
| NASDAQ | 22,788.98 | 157.50 | 0.70% |
| Nikkei 225 | 45,493.66 | 447.85 | 0.99% |
| NZX 50 Index | 13,136.44 | 5.10 | -0.04% |
| S&P 500 | 6,693.75 | 29.39 | 0.44% |
| S&P/ASX 200 | 8,857.20 | 25.60 | 0.29% |
| SSE Composite Index | 3,781.53 | 47.05 | -1.23% |